```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1         Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2         "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28  PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
 NEWS  4  FEB 28  BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02  GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03  REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS 10  MAR 22  PATDPASPC - New patent database available
 NEWS 11  MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS 12  APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS 13  APR 04  EMBASE - Database reloaded and enhanced
 NEWS 14  APR 18  New CAS Information Use Policies available online
 NEWS 15  APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS 16  APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
 NEWS 17  MAY 23  GBFULL enhanced with patent drawing images
 NEWS 18  MAY 23  REGISTRY has been enhanced with source information from
                  CHEMCATS
 NEWS 19  JUN 06  STN Patent Forums to be held in June 2005
 NEWS 20  JUN 06  The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available
 NEWS 21  JUN 13  RUSSIAPAT: New full-text patent database on STN
 NEWS 22  JUN 13  FRFULL enhanced with patent drawing images
 NEWS 23  JUN 20  MEDICONF to be removed from STN
 NEWS 24  JUN 27  MARPAT displays enhanced with expanded G-group definitions
                  and text labels
 NEWS 25  JUL 01  MEDICONF removed from STN
 NEWS 26  JUL 07  STN Patent Forums to be held in July 2005

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:49:29 ON 10 JUL 2005

=> file caplus
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.21       0.21

FILE 'CAPLUS' ENTERED AT 10:50:01 ON 10 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Jul 2005  VOL 143 ISS 3
FILE LAST UPDATED: 8 Jul 2005  (20050708/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> "HIV (l) RT mutation
MISMATCHED QUOTE '"HIV'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> HIV (l) "reverse transcripatase mutation"
         61151 HIV
            90 HIVS
         61166 HIV
                 (HIV OR HIVS)
        194820 "REVERSE"
          8154 "REVERSES"
        202154 "REVERSE"
                 ("REVERSE" OR "REVERSES")
             0 "TRANSCRIPATASE"
        220886 "MUTATION"
        143773 "MUTATIONS"
        275124 "MUTATION"
                 ("MUTATION" OR "MUTATIONS")
             0 "REVERSE TRANSCRIPATASE MUTATION"
                 ("REVERSE"(W)"TRANSCRIPATASE"(W)"MUTATION")
L1           0 HIV (L) "REVERSE TRANSCRIPATASE MUTATION"

=> reverse(w) transcriptase
        194820 REVERSE
          8154 REVERSES
        202154 REVERSE
                 (REVERSE OR REVERSES)
         28738 TRANSCRIPTASE
           731 TRANSCRIPTASES
         28877 TRANSCRIPTASE
                 (TRANSCRIPTASE OR TRANSCRIPTASES)
L2       28320 REVERSE(W) TRANSCRIPTASE
```

```
=> HIV
         61151 HIV
            90 HIVS
L3       61166 HIV
                 (HIV OR HIVS)

=> L2 and L3
L4        7571 L2 AND L3

=> mutation and L4
        220886 MUTATION
        143773 MUTATIONS
        275124 MUTATION
                 (MUTATION OR MUTATIONS)
L5        1695 MUTATION AND L4

=> "codon 245"
         34848 "CODON"
         15102 "CODONS"
         42188 "CODON"
                 ("CODON" OR "CODONS")
         27360 "245"
L6          29 "CODON 245"
                 ("CODON"(W)"245")

=> L5 and L6
L7           0 L5 AND L6

=> 245 and L5
         27360 245
L8           1 245 AND L5

=> D L8 IBIB ABS 1

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2005:424033  CAPLUS
TITLE:                    Impact of HIV-1 subtype and antiretroviral
                          therapy on protease and reverse
                          transcriptase genotype: Results of a global
                          collaboration
AUTHOR(S):                Kantor, Rami; Katzenstein, David A.; Efron, Brad;
                          Carvalho, Ana Patricia; Wynhoven, Brian; Cane,
                          Patricia; Clarke, John; Sirivichayakul, Sunee; Soares,
                          Marcelo A.; Snoeck, Joke; Pillay, Candice; Rudich,
                          Hagit; Rodrigues, Rosangela; Holguin, Africa;
                          Ariyoshi, Koya; Bouzas, Maria Belen; Cahn, Pedro;
                          Sugiura, Wataru; Soriano, Vincent; Brigido, Luis F.;
                          Grossman, Zehava; Morris, Lynn; Vandamme, Anne-Mieke;
                          Tanuri, Amilcar; Phanuphak, Praphan; Weber, Jonathan
                          N.; Pillay, Deenan; Harrigan, P. Richard; Camacho,
                          Ricardo; Schapiro, Jonathan M.; Shafer, Robert W.
CORPORATE SOURCE:         Division of Infectious Disease and Center for AIDS
                          Research, Stanford University, Stanford, CA, USA
SOURCE:                   PLoS Medicine (2005), 2(4), 325-337
                          CODEN: PMLEAC; ISSN: 1549-1277
                          URL: http://medicine.plosjournals.org/archive/1549-
                          1676/2/4/pdf/10.1371_journal.pmed.0020112-L.pdf
PUBLISHER:                Public Library of Science
DOCUMENT TYPE:            Journal; (online computer file)
LANGUAGE:                 English
AB   Background The genetic differences among HIV-1 subtypes may be
     critical to clin. management and drug resistance surveillance as
     antiretroviral treatment is expanded to regions of the world where diverse
     non-subtype-B viruses predominate.  Methods and Findings To assess the
     impact of HIV-1 subtype and antiretroviral treatment on the
     distribution of mutations in protease and reverse
     transcriptase, a binomial response model using subtype and
     treatment as explanatory variables was used to analyze a large compiled
     dataset of non-subtype-B HIV-1 sequences.  Non-subtype-B
     sequences from 3,686 persons with well characterized antiretroviral
     treatment histories were analyzed in comparison to subtype B sequences
     from 4,769 persons.  The non-subtype-B sequences included 461 with subtype
     A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with
     CRF01_AE, and 618 with CRF02_AG.  Each of the 55 known subtype B
     drug-resistance mutations occurred in at least one non-B
     isolate, and 44 (80%) of these mutations were significantly
     associated with antiretroviral treatment in at least one non-B subtype.
     Conversely, of 67 mutations found to be associated with
     antiretroviral therapy in at least one non-B subtype, 61 were also associated
     with antiretroviral therapy in subtype B isolates.  Conclusion Global
     surveillance and genotypic assessment of drug resistance should focus
     primarily on the known subtype B drug-resistance mutations.
REFERENCE COUNT:         49    THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> RT (w) mutation
         75056 RT
           996 RTS
         75678 RT
                 (RT OR RTS)
        220886 MUTATION
        143773 MUTATIONS
        275124 MUTATION
                 (MUTATION OR MUTATIONS)
L9          93 RT (W) MUTATION

=> L4 and L9
L10         83 L4 AND L9

=> 245 and L10
         27360 245
L11          0 245 AND L10

=> "non nucleoside reverse transcriptase inhibitor"
        729540 "NON"
            33 "NONS"
        729566 "NON"
                 ("NON" OR "NONS")
         43823 "NUCLEOSIDE"
         29969 "NUCLEOSIDES"
         54887 "NUCLEOSIDE"
                 ("NUCLEOSIDE" OR "NUCLEOSIDES")
        194820 "REVERSE"
          8154 "REVERSES"
        202154 "REVERSE"
                 ("REVERSE" OR "REVERSES")
         28738 "TRANSCRIPTASE"
           731 "TRANSCRIPTASES"
         28877 "TRANSCRIPTASE"
                 ("TRANSCRIPTASE" OR "TRANSCRIPTASES")
        478279 "INHIBITOR"
        492690 "INHIBITORS"
        763156 "INHIBITOR"
                 ("INHIBITOR" OR "INHIBITORS")
L12        642 "NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR"
                 ("NON"(W)"NUCLEOSIDE"(W)"REVERSE"(W)"TRANSCRIPTASE"(W)"INHIBIT
                 OR")

=> L12 and l4
L13        601 L12 AND L4

=> 245 and L13
         27360 245
L14          0 245 AND L13

=> L6 and L13
```

```
L15          0 L6 AND L13

=> L6 and RT
         75056 RT
           996 RTS
         75678 RT
                 (RT OR RTS)
L16          1 L6 AND RT

=> D L16 IBIB ABS

L16  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2000:4325  CAPLUS
DOCUMENT NUMBER:          132:249261
TITLE:                    GPI-anchored molecule-like protein (GML) expression in
                          non-small cell lung cancer (NSCLC)
AUTHOR(S):                Komiya, Takefumi; Hirashima, Tomonori; Kikui,
                          Masanori; Fukuoka, Masahiro; Ohno, Atsuko; Kawase,
                          Ichiro
CORPORATE SOURCE:         Department of Internal Medicine, Osaka Prefectural
                          Habikino Hospital, Habikino city, 583-8588, Japan
SOURCE:                   Anticancer Research (1999), 19(5B), 4315-4319
                          CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER:                International Institute of Anticancer Research
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   GPI-anchored mol.-like protein (GML) has been identified as a new target
     mol. of p53.  In esophageal cancer cell lines, expression of GML mRNA,
     which was found to be significantly correlated with in vitro anti-cancer
     drug sensitivity, was observed only in the presence of wild-type p53.  The
     relationship between expression of GML mRNA and p53 gene status in 24
     non-small cell lung cancer (NSCLC) cell lines was examined using RT
     -PCR and PCR-SSCP followed by direct DNA sequencing.  Results: Expression
     of GML mRNA was observed in only 3 of 24 cell lines.  In contrast to previous
     studies showing p53-dependent GML expression, of the 3 cell lines
     expressing GML mRNA, one had a p53 gene mutation (codon
     245: Gly to Cys).  These findings suggest that the expression of
     GML mRNA is infrequent and regulated in a p53-independent manner in NSCLC.
REFERENCE COUNT:          18    THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> L6 and HIV
         61151 HIV
            90 HIVS
         61166 HIV
                 (HIV OR HIVS)
L17          0 L6 AND HIV
```